|
KMID : 1134120070100030206
|
|
Journal of Breast Cancer
2007 Volume.10 No. 3 p.206 ~ p.210
|
|
|
Alteration of Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Breast Cancer after Neoadjuvant Chemotherapy
|
|
Lee Jong-Won
Im Seock-A
Oh Seung-Keun
Lee Ho-Chang
Youn Yeo-Kyu
Han Won-Shik
Roh Dong-Young
Park In-Ae
Hwang Ki-Tae
Kim Sung-Won
Keam Bhum-Suk
Ko Eun-Young
Cho Ji-hyoung
Jung So-Young
Kim Eun-Kyu
|
|
|
Abstract
|
|
|
Purpose: We aimed to assess the concordance of the im- munohistochemical profiles of core biopsy before adminis- trating neoadjuvant chemotherapy with that of the surgical specimens after a definitive operation for breast cancer.
Method: We retrospectively reviewed the estrogen receptor (ER), progesterone receptor (PR), and HER-2 expressions in 130 consecutive patients who received neoadjuvant che- motherapy and were followed by surgery during the period between February 2002 and March 2006. The pathologic complete tumor response rate for this group was 4.6% (6/ 130). Both the pre- and post-operative immunohistochemi- cal profiles were available in 32 of the 124 patients (25.8%). Immunohistochemical staining was done on the core biopsies before chemotherapy and on the surgical specimens after operation.
Results: There were 12 markers from 11 patients that were altered out of the 96 total markers (ER, PR, or HER-2) from 32 patients: 2 ER (2/12, 16.7%), 4 PR (4/12, 33.3%), and 6 HER-2 (6/12, 50.0%). One patient simultaneously had cha- nges in the expressions of PR and HER-2. Conversion of the hormone receptor status occurred in 3 patients (3/32, 9.4%): this was positive to negative in two, and vice versa in one. In addition, there were 6 conversions (6/32, 18.8%) of the HER-2 status from negative to positive.
Conclusions: The hormone receptor status changed in 9.4% of the 32 patients and the HER-2 status changed in 18.8% of the 32 patients after neoadjuvant chemotherapy. We have concluded that conducting only a single immunohistoche- mical study about ER, PR, and HER-2 may not be enough to exactly estimate the tumor marker status in the neoadju- vant setting.
|
|
|
KEYWORD
|
|
|
Breast cancer, Neoadjuvant chemotherapy, Tumor marker expre- ssion, Steroid hormone receptor, HER-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|